Farmas USA

ARNA

Arena Pharmaceuticals Reports Favorable Results from Phase 1 Single-Ascending Dose Clinical Trial of APD371

-- Results support advancement of the novel, oral drug candidate to the next stage of development --

SAN DIEGO, April 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases.

The randomized, double-blind and placebo-controlled Phase 1 clinical trial enrolled 56 healthy adults to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD371. Dose responsive exposure was observed over the explored dose range of 10-400 mg with good tolerability at all doses administered.

"In this trial, APD371 was well tolerated, as evidenced by the lack of dose-limiting adverse events, at drug levels greatly exceeding those anticipated as needed for activating the CB2 receptor," said William R. Shanahan, Jr., M.D., Arena's Senior Vice President and Chief Medical Officer. "We believe that the intrinsic properties of this compound could offer advantages over currently marketed treatments for pain."

About APD371

APD371, an orally available agonist of the CB2 receptor, is Arena's internally discovered investigational drug candidate for several potential indications, including pain and fibrotic diseases. This compound, through its high level of observed selectivity for the CB2 receptor versus the CB1 receptor, is designed to provide pain relief without psychotropic effects or the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in animal models of osteoarthritic and neuropathic pain.

CLSN

Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer

Programación fase 1 GEN 1 + avastatin + Doxil para el tercer trimestre

The Company announced plans today to expand its ovarian cancer development program to include a Phase 1 dose escalating trial evaluating GEN-1 in combination with Avastin® and Doxil® in platinum-resistant ovarian cancer patients, expected to begin in the second half of 2015. As previously reported, Celsion intends to commence a Phase 1b dose escalating trial in newly diagnosed ovarian cancer patients in the third quarter of this year.

Celsion intends to conduct additional preclinical studies to support an Investigational New Drug filing with the U.S. Food and Drug Administration for the planned Phase 1 combination study. The study will be designed to optimize the dosing regimen for GEN-1 in combination with Avastin® and is expected to enroll approximately 12 to 18 patients

The results of this important trial may therefore highlight additional therapeutic opportunities for GEN-1 and help guide how our development program evolves over the long term. We look forward to launching our study in first line ovarian cancer this year, followed by the launch of this combination trial, and then moving into clinical studies in a second tumor type, glioblastoma multiforme where Avastin® is currently used."

http://investor.celsion.com/releaseDetail.cfm?ReleaseID=909402

NVAX

Russell Rebalancing Will Bring Massive Buy Orders for 5 Key Stocks

Novavax Inc. (NASDAQ: NVAX) has been a very hot biotech stock and will see significant buying on the close Thursday. Jefferies thinks that a whopping 2,174,524 of the shares will be bought. We recently featured the company as one with explosive upside potential. The stock closed the trading day on Tuesday at $8.18.

http://247wallst.com/investing/2015/04/29/russell-rebalancing-will-bring-massive-buy-orders-for-5-key-stocks/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+typepad%2FRyNm+%2824%2F7+Wall+St.%29

Bien los earnings de CLDX, no puedo colgarlo,

Va:

http://www.smarteranalyst.com/2015/04/29/stock-update-nasdaqcldx-celldex-therapeutics-inc-reports-first-quarter-2015-results/

CLDX

uy que cosas mas bonitas posteas, Ana ... gracias

"Novavax Inc. (NASDAQ: NVAX) has been a very hot biotech stock and will see significant buying on the close Thursday. Jefferies thinks that a whopping 2,174,524 of the shares will be bought. We recently featured the company as one with explosive upside potential. The stock closed the trading day on Tuesday at $8.18.

con lo que me imagino que para lo que nos queda de semanita tendremos a NVAX coqueteando con los 8$ pelados sino es que tocamos los 7,7x de la alcista

NVAX

ONCY ¿alguna opinión de las oncológicas que matan a las malas a base de virus? En la la parte baja de canal y hoy tiene noticia positiva

TRISKIS, vas a recomprar cromos de THLD?

edito: he puesto orden de compra de unas pocas a 3,76 por si suena la flauta ...